Mainstay Lands $108M To Support Launch Of ReActiv8 Back Pain Device
The company has begun the US launch of the ReActiv8 implantable neurostimulator for treating low back pain in the US while expanding commercialization in Australia and Europe.
The company has begun the US launch of the ReActiv8 implantable neurostimulator for treating low back pain in the US while expanding commercialization in Australia and Europe.